Pharmaceutical firm NeoRx has received a small business innovative research (SBIR) grant from the National Cancer Institute to help bring the Seattle-based firm's Pretarget therapy radiopharmaceutical to clinical trials. The grant could be for as much as $950,000 to support testing of the agent, which is targeted at non-Hodgkin's lymphoma.
With Pretarget, the antibody and radionuclide are separately injected and subsequently joined at the tumor. Since the radionuclide is a small, drug-sized molecule, its circulation time is short, thus averting patient exposure to large amounts of radiation that are not targeted directly at the tumor, according to NeoRx.
By AuntMinnie.com staff writers
February 21, 2000
Copyright © 2000 AuntMinnie.com